Publications - Page 34 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP) 02/08/23
Pulmonary hypertension : A rare but severe complication of common variable immunodeficiency

Thoré P, Humbert M, Montani D.

Ann Allergy Asthma Immunol. 2021 Oct;127(4):512-513. Doi: 10.1016/j.anai.2021.06.016.
Hypertension pulmonaire (HTP) 02/08/23
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O.

Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. Doi: 10.1164/rccm.202009-3698OC.
Hypertension pulmonaire (HTP) 02/08/23
Pulmonary Hypertension in Patients with Common Variable Immunodeficiency

Thoré P, Jaïs X, Savale L, Dorfmuller P, Boucly A, Devilder M, Meyrignac O, Pichon J, Mankikian J, Riou M, Boiffard E, Boissin C, De Groote P, Chabanne C, Gagnadoux F, Bergeron A, Noel N, Sitbon O, Humbert M, Montani D.

J Clin Immunol. 2021 Oct;41(7):1549-1562. Doi: 10.1007/s10875-021-01064-w.
Hypertension pulmonaire (HTP) 02/08/23
Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database

Khouri C, Hlavaty A, Roustit M, Cracowski JL, Chaumais MC, Humbert M, Montani D.

Eur Respir J. 2021 Sep 29:2101576. Doi: 10.1183/13993003.01576-2021.
Hypertension pulmonaire (HTP) 02/08/23
Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH

Toshner M, Church C, Harbaum L, Rhodes C, Villar Moreschi SS, Liley J, Jones R, Arora A, Batai K, Desai AA, Coghlan JG, Gibbs JSR, Gor D, Gräf S, Harlow L, Hernandez-Sanchez J, Howard LS, Humbert M, Karnes J, Kiely DG, Kittles R, Knightbridge E, Lam B, Lutz KA, Nichols WC, Pauciulo MW, Pepke-Zaba J, Suntharalingam J, Soubrier F, Trembath RC, Schwantes-An TL, Wort SJ, Wilkins M, Gaine S, Morrell NW, Corris PA.

Eur Respir J. 2021 Sep 29:2002463. Doi: 10.1183/13993003.02463-2020.
Hypertension pulmonaire (HTP) 02/08/23
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort

Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Canuet M, Boissin C, Tromeur C, Chaouat A, Degano B, Bergot E, Sanchez O, Prevot G, Sitbon O, Thabut G, Belhadi D, de Beauregard YC, Bencherif A, Humbert M, Simonneau G, Laouenan C, Mal H.

J Heart Lung Transplant. 2021 Sep;40(9):1009-1018. Doi: 10.1016/j.healun.2021.04.021.
Hypertension pulmonaire (HTP) 02/08/23
A CELSR1 variant in a patient with pulmonary arterial hypertension

Eyries M, Girerd B, Savale L, Soubrier F, Humbert M, Montani D.

Clin Genet. 2021 Aug 25. Doi: 10.1111/cge.14046.
Hypertension pulmonaire (HTP) 02/08/23
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension

Bisserier M, Katz MG, Bueno-Beti C, Brojakowska A, Zhang S, Gubara S, Kohlbrenner E, Fazal S, Fargnoli A, Dorfmuller P, Humbert M, Hata A, Goukassian DA, Sassi Y, Hadri L.

Int J Mol Sci. 2021 Aug 24;22(17):9105. Doi: 10.3390/ijms22179105.
Hypertension pulmonaire (HTP) 02/08/23
Serum and pulmonary uric acid in pulmonary arterial hypertension

Savale L, Akagi S, Tu L, Cumont A, Thuillet R, Phan C, Le Vely B, Berrebeh N, Huertas A, Jaïs X, Cottin V, Chaouat A, Tromeur C, Boucly A, Jutant EM, Mercier O, Fadel E, Montani D, Sitbon O, Humbert M, Tamura Y, Guignabert C.

Eur Respir J. 2021 Aug 5;58(2):2000332. Doi: 10.1183/13993003.00332-2020.
Hypertension pulmonaire (HTP) 02/08/23
Association between Leflunomide and Pulmonary Hypertension

Palasset TL, Chaumais MC, Weatherald J, Savale L, Jaïs X, Price LC, Khouri C, Bulifon S, Seferian A, Jevnikar M, Boucly A, Manaud G, Pancic S, Chabanne C, Ahmad K, Volpato M, Favrolt N, Guillaumot A, Horeau-Langlard D, Prévot G, Fesler P, Bertoletti L, Reynaud-Gaubert M, Lamblin N, Launay D, Simonneau G, Sitbon O, Perros F, Humbert M, Montani D.

Ann Am Thorac Soc. 2021 Aug;18(8):1306-1315. Doi: 10.1513/AnnalsATS.202008-913OC.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Pulmonary hypertension : A rare but severe complication of common variable immunodeficiency

Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

Pulmonary Hypertension in Patients with Common Variable Immunodeficiency

Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database

Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH

Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort

A CELSR1 variant in a patient with pulmonary arterial hypertension

Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension

Serum and pulmonary uric acid in pulmonary arterial hypertension

Association between Leflunomide and Pulmonary Hypertension